Literature DB >> 34730398

SOSIP Trimer-Specific Antibodies Isolated from a Simian-Human Immunodeficiency Virus-Infected Monkey with versus without a Pre-blocking Step with gp41.

Natasha N Duggan1, Kim L Weisgrau2, Diogo M Magnani1, Eva G Rakasz2, Ronald C Desrosiers1, Jose M Martinez-Navio1.   

Abstract

BG505 SOSIP.664 (hereafter referred to as SOSIP), a stabilized trimeric mimic of the HIV-1 envelope spike resembling the native viral spike, is a useful tool for isolating anti-HIV-1 neutralizing antibodies. We screened long-term SHIV-AD8 infected rhesus monkeys for potency and breadth of serum neutralizing activity against autologous and heterologous viruses: SHIV-AD8, HIV-1 YU2, HIV-1 JR-CSF, and HIV-1 NL4-3. Monkey rh2436 neutralized all viruses tested and showed strong reactivity to the SOSIP trimer, suggesting this was a promising candidate for attempts at monoclonal antibody (MAb) isolation. MAbs were isolated by performing single B-cell sorts from peripheral blood mononuclear cells (PBMC) by FACS using the SOSIP trimer as a probe. An initial round of sorted cells revealed the majority of isolated MAbs were directed to the gp41 external domain portion of the SOSIP trimer and were mostly non-neutralizing against tested isolates. A second sort was performed, introducing a gp41 blocking step prior to PBMC staining and FACS sorting. These isolated MAbs bound SOSIP trimer but were no longer directed to the gp41 external domain portion. A significantly higher proportion of MAbs with neutralizing activity were obtained with this strategy. Our data show this pre-blocking step with gp41 greatly increases the yield of non-gp41-reactive, SOSIP-specific MAbs and increases the likelihood of isolating MAbs with neutralizing activity. IMPORTANCE Recent advancements in the field have focused on the isolation and use of broadly neutralizing antibodies for both prophylaxis and therapy. Finding a useful probe to isolate broad potent neutralizing antibodies while avoiding non-neutralizing antibodies is important. The SOSIP trimer has been shown to be a great tool for this purpose because it binds known broadly neutralizing antibodies. However, the SOSIP trimer can isolate non-neutralizing antibodies as well, including gp41-specific MAbs. Introducing a pre-blocking step with gp41 recombinant protein decreased the percent of gp41-specific antibodies isolated with SOSIP probe, as well as increased the number of neutralizing antibodies isolated. This method can be used as a tool to increase the chances of isolating neutralizing antibodies.

Entities:  

Keywords:  SHIV; SOSIP; gp41; monoclonal antibodies; neutralizing antibodies; rhesus macaques

Mesh:

Substances:

Year:  2021        PMID: 34730398      PMCID: PMC8791287          DOI: 10.1128/JVI.01582-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  62 in total

1.  Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Lingshu Wang; M Gordon Joyce; Zhi-Yong Yang; Alejandro B Balazs; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Rebecca S Rudicell; Ivelin S Georgiev; Lijie Duan; Kathryn E Foulds; Mitzi Donaldson; Ling Xu; Stephen D Schmidt; John-Paul Todd; David Baltimore; Mario Roederer; Ashley T Haase; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-08       Impact factor: 5.103

Review 2.  Restricted, canonical, stereotyped and convergent immunoglobulin responses.

Authors:  Carole J Henry Dunand; Patrick C Wilson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

3.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

4.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

5.  Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies.

Authors:  Thomas B Kepler; Hua-Xin Liao; S Munir Alam; Rekha Bhaskarabhatla; Ruijun Zhang; Chandri Yandava; Shelley Stewart; Kara Anasti; Garnett Kelsoe; Robert Parks; Krissey E Lloyd; Christina Stolarchuk; Jamie Pritchett; Erika Solomon; Emma Friberg; Lynn Morris; Salim S Abdool Karim; Myron S Cohen; Emmanuel Walter; M Anthony Moody; Xueling Wu; Han R Altae-Tran; Ivelin S Georgiev; Peter D Kwong; Scott D Boyd; Andrew Z Fire; John R Mascola; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2014-09-10       Impact factor: 21.023

Review 6.  Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Authors:  Sebastian P Fuchs; Ronald C Desrosiers
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-16       Impact factor: 6.698

7.  Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.

Authors:  Philip J M Brouwer; Aleksandar Antanasijevic; Marlon de Gast; Joel D Allen; Tom P L Bijl; Anila Yasmeen; Rashmi Ravichandran; Judith A Burger; Gabriel Ozorowski; Jonathan L Torres; Celia LaBranche; David C Montefiori; Rajesh P Ringe; Marit J van Gils; John P Moore; Per Johan Klasse; Max Crispin; Neil P King; Andrew B Ward; Rogier W Sanders
Journal:  NPJ Vaccines       Date:  2021-02-09       Impact factor: 7.344

8.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Authors:  Rogier W Sanders; Marit J van Gils; Ronald Derking; Devin Sok; Thomas J Ketas; Judith A Burger; Gabriel Ozorowski; Albert Cupo; Cassandra Simonich; Leslie Goo; Heather Arendt; Helen J Kim; Jeong Hyun Lee; Pavel Pugach; Melissa Williams; Gargi Debnath; Brian Moldt; Mariëlle J van Breemen; Gözde Isik; Max Medina-Ramírez; Jaap Willem Back; Wayne C Koff; Jean-Philippe Julien; Eva G Rakasz; Michael S Seaman; Miklos Guttman; Kelly K Lee; Per Johan Klasse; Celia LaBranche; William R Schief; Ian A Wilson; Julie Overbaugh; Dennis R Burton; Andrew B Ward; David C Montefiori; Hansi Dean; John P Moore
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

9.  Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows.

Authors:  Devin Sok; Khoa M Le; Melissa Vadnais; Karen L Saye-Francisco; Joseph G Jardine; Jonathan L Torres; Zachary T Berndsen; Leopold Kong; Robyn Stanfield; Jennifer Ruiz; Alejandra Ramos; Chi-Hui Liang; Patricia L Chen; Michael F Criscitiello; Waithaka Mwangi; Ian A Wilson; Andrew B Ward; Vaughn V Smider; Dennis R Burton
Journal:  Nature       Date:  2017-07-20       Impact factor: 49.962

10.  A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch.

Authors:  Zijun Wang; Christopher O Barnes; Rajeev Gautam; Julio C Cetrulo Lorenzi; Christian T Mayer; Thiago Y Oliveira; Victor Ramos; Melissa Cipolla; Kristie M Gordon; Harry B Gristick; Anthony P West; Yoshiaki Nishimura; Henna Raina; Michael S Seaman; Anna Gazumyan; Malcolm Martin; Pamela J Bjorkman; Michel C Nussenzweig; Amelia Escolano
Journal:  Elife       Date:  2020-10-21       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.